
Approved by MOG: Via Monthly Medicines Optimisation Group Meetings

| Ruxolitinib (INC424) Incyte® |
|
Formulary
|
Approved for 2nd line compassionate treatment in patients with high risk myelofibrosis (Cons. Haematologist) |
![]()
|
| Sativex “Cannabis Extract” |
|
Formulary
|
For muscle spasticity, to be funded by Neurosciences directorate |
![]()
|
